


Trilaciclib dihydrochloride

03/21

ALTERNATE NAMES: G1T28 dihydrochloride; 4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetraazatricyclo[7.4.0.0.2,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one;dihydrochloride

CATALOG #: B3120-5 5 mg
B3120-25 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₄H₃₂Cl₂N₈O

MOLECULAR WEIGHT: 519.5

CAS NUMBER: 1977495-97-8

APPEARANCE: Solid

PURITY: ≥ 97%

SOLUBILITY: ~1 mg/ml in DMSO (may need ultrasonication)

DESCRIPTION: Trilaciclib dihydrochloride is a CDK4/6 inhibitor which reduces chemotherapy-induced myelosuppression. It induces a G1 cell-cycle arrest in CDK4/6-dependent HS68 cells with an EC₅₀ of 30 nM. It is used to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy.

STORAGE TEMPERATURE: -20 °C

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCE: Bisi, J.E., Sorrentino, J.A., Roberts, P.J. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. *Mol Cancer Ther.* 15(5):783-93 (2016).

RELATED PRODUCTS:

SW-033291 (Cat. No. 9584)
 Riviciclib hydrochloride (Cat. No. B2567)
 EZSolution™ AZD-5438 (Cat. No. B2624)
 Cdk4 Inhibitor (Cat. No. B2928)
 Roscovitine (Cat. No. 1950)

DISCLAIMER: **FOR RESEARCH USE ONLY! Not to be used on humans.**